Search results for "analgesic"

showing 10 items of 365 documents

Prenatal cocaine alters later responses to morphine in adult male mice.

2006

Mice prenatally exposed to cocaine (25 mg/kg), physiological saline or non-treated during the last 6 days of pregnancy were evaluated as adults for the rewarding properties of 2 mg/kg of morphine, using the conditioned place preference (CPP) procedure. Likewise, isolated animals underwent a social interaction test with conspecifics after receiving the same morphine dose. Unlike control or animals pre-treated with saline, subjects prenatally treated with cocaine did not develop CPP with this dose of morphine. Only cocaine-exposed animals showed increased threat, avoidance and fleeing during the social encounter. No differences in motor effects of morphine were observed. Analysis of monoamine…

Malemedicine.medical_specialtyBiogenic AminesOffspringmedicine.medical_treatmentPharmacologyMotor ActivityMiceCocaineRewardPregnancyInternal medicinemedicineAnimalsInterpersonal RelationsSalineBiological PsychiatryPharmacologyBrain ChemistryPregnancyBehavior AnimalMorphinePrenatal cocaine exposuremedicine.diseaseConditioned place preferenceAggressionAnalgesics OpioidMonoamine neurotransmitterEndocrinologyPrenatal Exposure Delayed EffectsToxicityMorphineExploratory BehaviorConditioning OperantFemalePsychologymedicine.drugProgress in neuro-psychopharmacologybiological psychiatry
researchProduct

Évaluation de la prescription des antalgiques de palier II chez la personne âgée de 75 ans en médecine générale

2017

Although step-2 analgesics (S2A) are recommended when step-1 analgesics (S1A) are ineffective or in cases of moderate to severe pain, their efficacy varies. This study evaluated the place attributed by general practitioners (GPs) to S2A in the treatment of nociceptive pain in elderly persons (EP). Descriptive, transversal and declarative study conducted among GPs in Burgundy. In total, 115 GPs took part in the survey. Among these, 60.8% had at least one consultation/day for pain. After paracetamol, which was systematically preferred, 56.4% prescribed S2A for EP. The reasons for prescribing S2A included pain not relieved by S1A in 93% of cases, another medical treatment or not (42.6%), or th…

Malemedicine.medical_specialtyConstipationNauseaAnalgesic[ SDV.MHEP.GEG ] Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontologyDrug Prescriptionspersonne âgéeAmbulatory careGeneral PractitionersmedicineHumansPain ManagementMedical prescriptionAdverse effectBiological PsychiatryAgedAged 80 and overAnalgesics[SDV.MHEP.GEG] Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontologybusiness.industryChronic painmedicine.diseaseDrug Utilizationmédecine généraleNeuropsychology and Physiological PsychologyHealth Care Surveysantalgiques de palier IIVomitingPhysical therapyFemaleFranceNeurology (clinical)Chronic PainGeriatrics and Gerontologymedicine.symptombusinessGériatrie et Psychologie Neuropsychiatrie du Viellissement
researchProduct

Meaningful cut-off pain intensity for breakthrough pain changes in advanced cancer patients

2013

Abstract OBJECTIVES: To assess the level of pain intensity at which patients feel the impetus to ask for a breakthrough cancer pain (BTcP) medication, and level of pain intensity at which patients consider they have achieved acceptable pain control after receiving a BTcP medication. METHODS: A consecutive sample of patients who were receiving oral morphine equivalents equal to or more than 60 mg daily, and were prescribed rapid onset opioids for the management of episodes of BTcP, were included in the study. Focused educational activities regarding BTcP and numerical scales were established during hospital admission. At discharge patients were interviewed to find out what was the pain inten…

Malemedicine.medical_specialtyCoping (psychology)Palliative careBreakthrough PainPainSettore MED/42 - Igiene Generale E ApplicataCONSECUTIVE SAMPLEadvanced cancer patientNeoplasmsHumansPain ManagementMedicineOral morphineAgedPain MeasurementMorphinebusiness.industrybreakthrough pain; advanced cancer patients; epidemiologic studyGeneral MedicineMiddle Agedbreakthrough painAdvanced cancerAnalgesics OpioidClinical trialepidemiologic studyPhysical therapyFemalebusinessCancer pain
researchProduct

Serum dehydroepiandrosterone sulfate and osteoarthritis in older people: the Pro.V.A. study.

2016

Although osteoarthritis (OA) and low levels of dehydroepiandrosterone sulfate (DHEAS) are common in the elderly, no studies on human beings are available concerning the possible relationship between them. We aimed to examine the relationship between DHEAS levels and any presence of OA in a cohort of community-dwelling older subjects. This study was part of the Progetto Veneto Anziani (Pro.V.A.), an Italian population-based cohort study on people over 65 years old. In this cross-sectional work, we considered 2050 individuals with a mean age of 74.2 ± 7.1 years (818 M and 1232 F), and with a complete set of information on OA and DHEAS levels. OA was defined using a standardized algorithm inve…

Malemedicine.medical_specialtyDHEASPhysical examinationOsteoarthritis030204 cardiovascular system & hematologyLogistic regressionNO03 medical and health scienceschemistry.chemical_compoundCommunity-dwelling adults DHEAS Elderly Osteoarthritis0302 clinical medicineDehydroepiandrosterone sulfateElderlyRheumatologyInternal medicineOsteoarthritismedicineCommunity-dwelling adults; DHEAS; Elderly; Osteoarthritis; RheumatologyHumansAgedAged 80 and overAnalgesics030214 geriatricsmedicine.diagnostic_testbusiness.industryDehydroepiandrosterone SulfateConfoundingGeneral Medicinemedicine.diseaseCommunity-dwelling adultsRheumatologyCross-Sectional StudieschemistryItalyCohortPhysical therapyFemalebusinessCohort studyClinical rheumatology
researchProduct

Relationship between background cancer pain, breakthrough pain, and analgesic treatment: a preliminary study for a better interpretation of epidemiol…

2020

Abstract Abstract Background: The different operational definitions of breakthrough cancer pain (BTcP) has generated unclear epidemiological data. Methods: A consecutive sample of patients was categorized on the basis of their background pain intensity, background analgesic treatment, and the presence of BTcP. Results: A total of 265 patients were surveyed; 117 patients had background pain and 91 patients presented peaks of pain intensity distinguishable from background pain. Of 117 patients with background pain, 49 patients were re-assessed after optimization of background analgesia (T1) within a mean of 8.2 days. Pain intensity significantly decreased in comparison with values recorded at…

Malemedicine.medical_specialtyEpidemiologyBreakthrough PainAnalgesicOpioidSettore MED/42 - Igiene Generale E ApplicataCONSECUTIVE SAMPLENeoplasmsSurveys and QuestionnairesEpidemiologyMedicineHumansPain ManagementCancer painPain MeasurementAnalgesicsbackground cancer painbusiness.industryMedicine (all)General MedicineBreakthrough pain; Cancer pain; Epidemiology; Opioids; Analgesics Opioid; Breakthrough Pain; Female; Humans; Male; Neoplasms; Pain Management; Pain Measurement; Surveys and Questionnaires; Medicine (all)breakthrough painIntensity (physics)OpioidsAnalgesics OpioidAnesthesiaepidemiologic studyFemaleCancer painbusinessbackground cancer pain; breakthrough pain; epidemiologic study
researchProduct

Impact of comorbidities on pharmacotherapy of painful diabetic neuropathy in clinical practice.

2014

Abstract Aims We evaluated the impact of baseline comorbidities on the effectiveness of duloxetine and anticonvulsants (pregabalin/gabapentin) in patients with painful diabetic neuropathy in clinical care. Methods Outcomes from a 6-month, observational study with 2575 patients initiating/switching DPNP treatment were analyzed post-hoc. Propensity scoring was used to adjust for baseline factors influencing treatment choice in 1523 patients receiving duloxetine or anticonvulsants. Analysis of covariance models with fixed effects for baseline pain, treatment, propensity score, baseline characteristics or comorbidities, and their interaction with treatment were used to estimate LSmean effects o…

Malemedicine.medical_specialtyGabapentinCyclohexanecarboxylic AcidsEndocrinology Diabetes and MetabolismPregabalinPregabalinComorbidityThiophenesDuloxetine Hydrochloridechemistry.chemical_compoundEndocrinologyDiabetic NeuropathiesInternal MedicinemedicineDuloxetineHumansPain ManagementBrief Pain InventoryAminesDepression (differential diagnoses)gamma-Aminobutyric AcidAgedPain MeasurementRetrospective StudiesAnalgesicsbusiness.industryChronic painMiddle Agedmedicine.diseasePrognosisTreatment OutcomechemistryJoint painPropensity score matchingPhysical therapyAnticonvulsantsFemalemedicine.symptomGabapentinbusinessmedicine.drugJournal of diabetes and its complications
researchProduct

Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone

2011

none 25 no Abstract OBJECTIVES: To evaluate the incidence and dose-dependency of mitoxantrone (MTX)-associated acute myelocytic leukemia (AML) in the network of Italian multiple sclerosis (MS) clinics. METHODS: We performed a multicenter retrospective cohort study of patients treated with MTX in MS centers under the Italian national health care system between 1998 and 2008. Demographic, disease, treatment, and follow-up information were collected using hospital records. RESULTS: Data were available for 3,220 patients (63% women) from 40 Italian centers. Follow-up (mean ± SD) was 49 ± 29 months (range 12-140 months). We observed 30 cases of AML (incidence 0.93% [95% confidence interval 0.60%…

Malemedicine.medical_specialtyMyeloidmitoxantrone; acute myelocytic leukemia; multiple sclerosisPopulationmultiple sclerosisStatistics NonparametricmitoxantroneFollow-Up StudieArts and Humanities (miscellaneous)Retrospective StudieInternal medicineMultiple SclerosimedicineHumansmultiple sclerosis leukemia mitoxantroneProspective cohort studyeducationRetrospective StudiesAgedAnalgesicseducation.field_of_studyMitoxantroneCumulative dosebusiness.industryMultiple sclerosisIncidence (epidemiology)leukemiaMyeloid leukemiaRetrospective cohort studymedicine.diseaseConfidence intervalSurgeryLeukemiaLeukemia Myeloid Acutemedicine.anatomical_structureItalyCohortSettore MED/26 - NeurologiaAnalgesicFemaleNeurology (clinical)acute myelocytic leukemiaMitoxantronebusinessFollow-Up Studiesmedicine.drugHuman
researchProduct

Tools for identifying cancer pain of predominantly neuropathic origin and opioid responsiveness in cancer patients.

2009

Neuropathic pain (NP) is a difficult issue, particularly in cancer which is a dynamic condition where multiple pain etiologies are concomitantly present. Cancer pain is often labeled as mixed mechanism pain and is not easily classified as exclusively nociceptive or NP. The aim of this study was to explore the value of evaluation tools such as Neuropathic Pain Questionnaire (NPQ), complete and short form (NPQ-SF), Leeds Assessment of Neuropathic Signs and Symptoms (LANSS) and Neuropathic Pain Symptom Inventory (NPSI). The secondary outcome was to evaluate the response to opioid titration, according to the hierarchical classification of definite, possible and unlikely NP. A consecutive sample…

Malemedicine.medical_specialtyPainOpioidSensitivity and SpecificityRoute of administrationassessment toolsInternal medicineNeoplasmsmedicineassessment tools; Cancer pain; neuropathic pain; opioid response; Aged; Analgesics Opioid; Female; Humans; Male; Neoplasms; Pain; Pain Measurement; Sensitivity and Specificity; Treatment Outcome; Anesthesiology and Pain Medicine; Neurology; Neurology (clinical)HumansCancer painAgedPain Measurementtools for cancer painneuropathic painopioid responsivenessAnalgesicsbusiness.industryCancerPain scaleneuropathic cancer painmedicine.diseaseAnalgesics OpioidAnesthesiology and Pain MedicineNociceptionTreatment OutcomeNeurologyOpioidopioid responseAnesthesiaNeuropathic painEtiologyFemaleNeurology (clinical)businessCancer painmedicine.drugThe journal of pain
researchProduct

Breakthrough Pain in Advanced Cancer Patients Followed at Home: A Longitudinal Study

2009

The aim of this study was to longitudinally assess breakthrough pain (BP) in advanced cancer patients who were admitted to home palliative care. One hundred and one consecutive patients who were admitted to one of the two home care programs and were representative of the cancer population followed at home in Italy were included. Patients were excluded only if at admission they were cognitively impaired or too unwell to provide reliable answers to questions regarding data collection. At admission (T(0)), and one month later (T(1)), data were recorded about the pharmacological treatment of background pain and its effectiveness; the presence of BP and its intensity, duration, and number of epi…

Malemedicine.medical_specialtyPalliative careAnalgesicPopulationPainComorbidityRisk AssessmentMedication prescriptionadvanced cancer patientRisk FactorsNeoplasmsInternal medicineBreakthrough painmedicineHumansLongitudinal StudieseducationSurvival rateGeneral NursingAgededucation.field_of_studybusiness.industryIncidenceIncidence (epidemiology)longitudinal studymedicine.diseaseHome Care ServicesSurvival AnalysisComorbiditySurvival RateAnesthesiology and Pain MedicineItalyPhysical therapyFemaleNeurology (clinical)businessCancer painJournal of Pain and Symptom Management
researchProduct

Clinical and financial analysis of an acute palliative care unit in an oncological department

2008

The aim of this article is to describe the clinical activity and medical intervention of an acute model of palliative care unit (APC), as well as the reimbursement procedures and economic viability. A sample of 504 patients admitted at an APC in 1 year was surveyed. Indications for admission, pain and symptom intensity, analgesic treatments, procedures, instrumental examinations and modalities of discharge were recorded. For each patient, tariff for reimbursement was calculated according to the existent disease related grouping (DRG) system. The mean age was 62 years, and 246 patients were males. The mean hospital stay was 5.4 days. Pain control was the most frequent indication for admissi…

Malemedicine.medical_specialtyPalliative carePainSettore MED/42 - Igiene Generale E ApplicataUnit (housing)Economic viabilityIntervention (counseling)NeoplasmscostmedicineFinancial analysisTerminal careHumansProspective StudiesIntensive care medicinepain and symptom controlReimbursementCancerTerminal Carepalliative carebusiness.industryDelivery of Health Care IntegratedGeneral MedicineMiddle AgedAnalgesics OpioidAnesthesiology and Pain MedicineTreatment OutcomeItalyEmergency medicineInsurance Health ReimbursementFemaleOpioid analgesicsbusinessErythrocyte TransfusionDelivery of Health Care
researchProduct